A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Rituximab (Primary) ; Carboplatin; Cyclophosphamide; Cytarabine; Etoposide; Etoposide phosphate; Filgrastim; Pegfilgrastim; Sodium thiosulfate
- Indications CNS cancer; Lymphoma; Thrombocytopenia
- Focus Therapeutic Use
- 10 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Jun 2010 Planned end date changed from 1 Jun 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.